Alvotech (NasdaqGM:ALVO) opened 2026 with Q1 revenue of US$105.9 million and basic EPS of US$0.00, alongside net income of US$1.0 million, marking a quarter where the income line moved into positive territory. The company has seen revenue range from US$153.3 million in Q4 2024 to US$168.9 million in Q4 2025, while quarterly EPS has swung between a loss of US$0.87 on a trailing twelve month basis in Q4 2024 and a gain of US$0.39 in Q1 2025 as net income shifted between profits and losses. For investors, that mix of positive quarterly EPS against still loss making trailing twelve month figures sets up a story focused on how durable the current margin profile really is.

See our full analysis for Alvotech.

With the headline numbers on the table, the next step is to see how this earnings profile lines up with the key narratives around Alvotech's growth potential and risk profile, and where those stories are reinforced or challenged by the latest margins.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

US$562 million in trailing revenue, but 12 month loss still on the books

• Over the last twelve months, Alvotech generated US$562.0 million of revenue and reported a net loss of US$80.7 million, compared with single quarter net income of US$1.0 million in Q1 2026.
• Consensus narrative points to a long term path toward higher margins. However, the trailing loss of US$80.7 million and trailing EPS of US$0.28 loss contrast with expectations that margins move from a 14.4% loss to 21.6% profit, highlighting that the current profitability base is still low relative to those goals.
  • Analysts reference revenue growth assumptions of 22.6% a year, but the latest trailing revenue of US$562.0 million is still paired with losses rather than the positive earnings those forecasts work toward.
  • The US$1.0 million profit in Q1 2026 follows periods where quarterly net income swung from a US$109.7 million profit in Q1 2025 to a US$108.5 million loss in Q4 2025, so earnings consistency is not yet in place even as the long term story assumes much steadier profits.

Valuation gap between US$4.16 price and DCF fair value of US$11.80

• The stock trades at about US$4.16, with a P/S of 2.3x versus peer and industry averages of 5.3x and 10.5x, and a DCF fair value of roughly US$11.80, while the consensus analyst price target sits at about US$13.83.
• Bulls argue that forecast revenue growth of around 24.5% a year and margin expansion from 4.7% to 28.7% justify a high future P/E. However, the current P/S discount and the gap between US$4.16 and both the US$11.80 DCF fair value and the US$13.83 analyst target show the market is not fully aligning with those optimistic assumptions.
  • The bullish narrative ties that upside to potential earnings of US$326.3 million by 2029, but the latest trailing net loss of US$80.7 million underlines how far current earnings are from that level.
  • Supporters point to reduced losses over five years at about 16.2% per year and current pricing well below both peer P/S multiples and DCF fair value. Yet the move from loss making to those projected margins would require a sustained improvement compared with the mixed quarterly pattern seen between Q1 2025 and Q4 2025.

For a closer look at how bullish investors connect these growth and margin assumptions to valuation at today’s share price, have a look at the 🐂 Alvotech Bull Case.

Balance sheet strain with negative equity and high debt

• Alvotech carries about US$1.1b of debt alongside US$151 million of cash, while also having negative shareholders’ equity and less than one year of cash runway flagged as key financial risk signals.
• Bears highlight that this leverage and weak equity position leave little room for error, and the trailing net loss of US$80.7 million together with volatile quarterly net income movements supports their concern that debt servicing and funding capital heavy R&D could pressure future results if the business does not generate steadier profits.
  • The shift from a trailing profit of US$27.9 million at Q4 2025 to a trailing loss of US$80.7 million at Q1 2026 shows how quickly the income line can move, which matters when debt of about US$1.1b sits on the balance sheet.
  • Recent three month share price volatility and the shorter cash runway cited in the risk summary also fit the cautious view that, even with growth forecasts in place, balance sheet strength is a key issue to track alongside the income statement.

Skeptics focus heavily on these balance sheet pressures, so if you want to see how they frame the downside case in detail, check out the 🐻 Alvotech Bear Case.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Alvotech on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With both upside potential and clear risks on the table, how does this balance of reward and concern sit with you today? Act while the details are fresh in mind and weigh the trade off yourself by checking the 3 key rewards and 3 important warning signs.

See What Else Is Out There

Alvotech pairs a trailing net loss of US$80.7 million with negative equity and sizeable debt, so earnings quality and balance sheet resilience remain key concerns.

If that mix of losses, leverage and short cash runway feels uncomfortable, you might compare it with companies screened for stronger financial footing by checking the solid balance sheet and fundamentals stocks screener (46 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.